Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

Several other research firms have also issued reports on ICPT. Cowen restated an “outperform” rating and issued a $232.00 price objective on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. Goldman Sachs Group restated a “neutral” rating and issued a $79.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Cantor Fitzgerald restated an “underweight” rating and issued a $69.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Leerink Swann dropped their price objective on Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating on the stock in a research note on Saturday, September 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $144.13.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $0.22 during trading hours on Thursday, reaching $61.68. The company’s stock had a trading volume of 487,934 shares, compared to its average volume of 649,426. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 12-month low of $54.98 and a 12-month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s revenue for the quarter was up 697.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($3.59) earnings per share. equities research analysts predict that Intercept Pharmaceuticals will post -13.35 EPS for the current fiscal year.

In related news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 2,566 shares of company stock worth $151,025 in the last three months. 9.20% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of ICPT. Senvest Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at $33,883,000. Balyasny Asset Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter valued at $13,766,000. Vanguard Group Inc. boosted its holdings in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 17.0% in the 2nd quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after purchasing an additional 41,856 shares in the last quarter. Finally, Quantitative Investment Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter valued at $3,728,000. 73.80% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Intercept Pharmaceuticals (ICPT) Rating Lowered to Sell at BidaskClub” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/09/intercept-pharmaceuticals-icpt-rating-lowered-to-sell-at-bidaskclub.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.